These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
411 related items for PubMed ID: 20941938
1. [Proposal for biologic drugs therapy in rheumatoid arthritis]. Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S, Kaliterna DM, Hanih M, Novak S. Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938 [Abstract] [Full Text] [Related]
2. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis]. Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S. Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266 [Abstract] [Full Text] [Related]
3. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis]. Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S. Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272 [Abstract] [Full Text] [Related]
4. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. Gibbons LJ, Hyrich KL. BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652 [Abstract] [Full Text] [Related]
5. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors]. Swierkot J, Madej M. Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177 [Abstract] [Full Text] [Related]
6. New therapies for treatment of rheumatoid arthritis. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. Lancet; 2007 Dec 01; 370(9602):1861-74. PubMed ID: 17570481 [Abstract] [Full Text] [Related]
7. Rheumatoid arthritis: Biological therapy other than anti-TNF. Rossi D, Modena V, Sciascia S, Roccatello D. Int Immunopharmacol; 2015 Aug 01; 27(2):185-8. PubMed ID: 25840282 [Abstract] [Full Text] [Related]
8. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL. J Rheumatol; 2011 Nov 01; 38(11):2355-61. PubMed ID: 21885487 [Abstract] [Full Text] [Related]
9. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Papagoras C, Voulgari PV, Drosos AA. Autoimmun Rev; 2010 Jun 01; 9(8):574-82. PubMed ID: 20433955 [Abstract] [Full Text] [Related]
10. [Biologic therapy of rheumatoid arthritis]. Damjanov N, Vojinović J. Srp Arh Celok Lek; 2009 Jun 01; 137(3-4):205-10. PubMed ID: 19459571 [Abstract] [Full Text] [Related]
11. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations]. Nasonov EL. Ter Arkh; 2007 Jun 01; 79(5):5-8. PubMed ID: 17672066 [No Abstract] [Full Text] [Related]
15. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Belmonte Serrano MA, Pincus T. Rheumatology (Oxford); 2010 Sep 01; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342 [No Abstract] [Full Text] [Related]
18. Targeted therapy in rheumatoid arthritis. Köller MD. Wien Med Wochenschr; 2006 Jan 01; 156(1-2):53-60. PubMed ID: 16465614 [Abstract] [Full Text] [Related]
19. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. Rigby WF, Mease PJ, Olech E, Ashby M, Tole S. J Rheumatol; 2013 May 01; 40(5):599-604. PubMed ID: 23547218 [Abstract] [Full Text] [Related]